Breast Cancer

November 29th 2024

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) compared with standard-of-care treatments for patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer.

November 23rd 2024

Younger women with estrogen receptor (ER)–positive, HER2-negative breast cancer have significantly worse long-term outcomes, including higher rates of recurrence and metastasis, compared with older women.

November 19th 2024

Older non-Hispanic Black adults with early-stage breast cancer are less likely to receive timely treatment and guideline-concordant care, increasing their risk of death compared with non-Hispanic White women.

October 24th 2024

Medicaid expansion is associated with improved care and increased survival rates for patients with certain breast cancers, but future studies should focus on whether Medicaid expansion mitigates the disparities between Black and non-White patients.